Meridamycin analogues for the treatment of neurodegenerative disorders

A compound of the structure:

• wherein:
• R1 and R2 are, independently selected from the group consisting of, OH, oxo, O(C1 to C6 alkyl), O(substituted C1 to C6 alkyl), O(acyl), O(aryl), O(substituted aryl), O(heterocyclyl), or O(substituted heterocyclyl);
• R3, R5, and R6 are independently are selected from the group consisting of OH, oxo, O(C1 to C6 alkyl), O(substituted C1 to C6 alkyl), O(acyl), O(aryl), O(substituted aryl), O(heterocyclyl), and O(substituted heterocyclyl);
• R4 is selected from the group consisting of oxo, O(C1 to C6 alkyl), O(substituted C1 to C6 alkyl), O(acyl), O(aryl), O(substituted aryl), O(heterocyclyl), and O(substituted heterocyclyl);
• or
• R3 and R4 and/or R5 and R6 are joined together to form a structure:
• or, R4 and R5 are joined to form a structure:
• wherein X and Y are independently selected from the group consisting of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, aryl, substituted aryl, heterocyclyl, and substituted heterocyclyl;
• wherein the alkyl is substituted with one to three substituents each independently selected from halogen, CN, OH, NO2, amino, aryl, heterocyclyl, substituted aryl, substituted heterocyclyl, alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, alkylcarbonyl, alkylcarboxy, alkylamino, and arylthio;
• wherein aryl is a carbocyclic aromatic system having a single ring or multiple aromatic rings fused or linked together forming a conjugated aromatic system and wherein the aryl can be optionally substituted with one to four substituents each independently selected from halogen, CN, OH NO2, amino, aryl, heterocyclyl, substituted aryl, substituted heterocyclyl, alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, alkylcarbonyl, alkylcarboxy, alkylamino, and arylthio;
• wherein heterocyclyl is a 4- to 7-membered monocyclic or stable multicyclic heterocyclyl ring, which is saturated, partially saturated, or unsaturated, including carbon atoms and from one to four heteroatoms selected from N, O and S;
• and may be optionally substituted with one to four substituents each independently selected from halogen, CN, OH NO2, amino, aryl, heterocyclyl, substituted aryl, substituted heterocyclyl, alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, alkylcarbonyl, alkylcarboxy, alkylamino, and arylthio;
• wherein the acyl is an RCO group, where R is a C1 to C6 alkyl or substituted C1 to C6 alkyl as defined above and the point of attachment is on the carbon atom
• R7 is CH2, CHOH, or C═O;
• and
• n is 1 or 2;
• or a pharmaceutically acceptable salt thereof.